Background {#Sec1}
==========

We have recently reported that δ-tocotrienol is a potent anti-cancer agent (liver, pancreas, prostrate, breast cancer cell lines, Hela, melanoma, B lymphocytes and T-cells), and also a modulator of proteasome function, as compared to other outstanding proteasome inhibitors (thiostrepton, 2-methoxyestradiol, and quercetin) \[[@CR1]\]. Moreover, plasma total mRNAs obtained from δ-tocotrienol treated hepatitis C patients showed significant inhibition in the expression of pro-inflammatory cytokines (TNF-α and VCAM-1), and induction in expression of ICAM-1, IFN-γ, whereas proteasome subunits X, Y, Z, LMP7, LMP2, LMP10 (22--44%) were significantly inhibited compared to pre-dose values, and this down-regulation of proteasome subunits leads to autophagy and apoptosis of cells \[[@CR1]\]. The present study is an extension of these findings to study the effect of δ-tocotrienol (Fig. [1](#Fig1){ref-type="fig"}) treatment of chronic hepatitis C patients in their plasma mRNAs using RNA-Sequencing by Ingenuity Pathway Analysis (IPA). The viral infection with hepatitis C is responsible for a vast majority of chronic hepatitis cases over 180 million people worldwide, which is further supported by epidemiological and clinical studies have also demonstrated a causative role of viral infection of hepatitis C in the development of hepatocellular carcinoma \[[@CR2]\]. These figures are alarming, as patients currently asymptomatic with relatively mild disease may eventually progress to complications of chronic liver diseases, like cirrhosis, and hepatocellular carcinoma \[[@CR3]\]. The mechanisms of liver disease are not fully understood.Fig. 1Chemical structure of δ-tocotrienol (similar figure was published in our publication-54. Qureshi et al., Journal of Clinical & Experimental Cardiology. 2015;6:4. 10.4172/2155-9880.1000367 \[[@CR54]\]

The mechanisms that contribute to the pathogenesis of hepatitis virus-related liver infections are diverse and very complex. Investigation of altered cellular mechanisms through gene profiling techniques has improved the clear understanding of various disease processes and development of novel therapeutic targets \[[@CR4]\]. Earlier, techniques applied for studying gene expression profiling included microarrays, which analyzes quantitative expression of thousands of genes, and time consuming real-time PCR assays that gives only small number of expression of genes. These tools have been used previously for identification of differentially expressed genes in hepatitis C virus associated cirrhosis and carcinoma \[[@CR5]\]. In summary, these changes in gene expression were associated with immune response, fibrosis, cellular growth, proliferation, and apoptosis \[[@CR5]--[@CR7]\]. Nowadays, similar estimation carried out by RNA-sequence procedure, which will provide very accurate gene expression of several virus important biological functions and biomarkers.

The genotype hepatitis C is an important determinant of the response to treatment, and differences found in clinical outcomes of the disease with respect to infection of various genotypes \[[@CR6]--[@CR8]\]. The genotype 3 is the most prevalent genotype around the world compared to other genotype infection \[[@CR8]\]. In the present study we will identify altered cellular processes in chronic hepatitis C patients after treatment with δ-tocotrienols. The main purpose of this preliminary study was to isolate plasma total mRNAs from a few participants after δ-tocotrienol treatment of chronic hepatitis C patients, and to carry out RNA-sequence analysis, which quantified mRNA expression of a large number of genes in pooled specimens of pre-dose versus post-dose of δ-tocotrienol treatment of chronic hepatitis C patients. The gene expression data was analyzed by "Ingenuity Pathway Analysis", which would reveal the cellular and biological mechanisms at the molecular level in plasma total mRNAs obtained from chronic hepatitis C patients.

Methods {#Sec2}
=======

Materials {#Sec3}
---------

DeltaGold 125 mg softgels from annatto seeds (typical composition 90% δ-tocotrienol and 10% γ-tocotrienol) were supplied by American River Nutrition, Inc. (Hadley, MA, USA). RNeasy mini kit was obtained from QIAGEN Sciences (Germantown, MD, USA).

Impact of δ-tocotrienol in chronic hepatitis C patients {#Sec4}
-------------------------------------------------------

The study was carried out in Pakistan Ordinance Factory (POF) Hospital, Wah Cantonment, Rawalpindi, Pakistan; in collaboration with department of biomedical Sciences, University of Missouri-Kansas City, MO, USA. The study protocol was registered (IRB \# 129--2015) was approved by Institutional Review Board of POF, Rawalpindi, Pakistan. The study was carried out under a FDA approved IND number 36906**.** The hepatitis C antibody test was purchased from Sigma Chemical Co., St. Louis, USA. The second diagnosing hepatitis C test is RNA PCR test was obtained from the EDTA treated fresh whole blood by using total RNA purification kit \# 17200 (NORGEN Bioteck Corporation, Thorold, ON, Canada).

RNA-Sequence Analyses of plasma total RNAs obtained from EDTA treated whole blood after feeding δ-tocotrienol for 6-weeks to hepatitis C patients {#Sec5}
-------------------------------------------------------------------------------------------------------------------------------------------------

The details of study design, inclusion/exclusion criteria, experimental design, and physical characteristics of hepatitis C patients were same as reported \[[@CR1]\]. In short, the total mRNA was extracted from plasma of EDTA treated fresh whole blood of each hepatitis C patients (*n* = 14) fed δ-tocotrienol (500 mg/d) for 6 weeks by total RNA purification kit (NORGEN Bioteck Corporation, Thorold, ON, Canada). The purity of total RNAs (stored − 80 °C) was estimated by the ratios of 260/280 (2.02--2.08) of all samples, which was determined using Thermo Scientific NanoDrop 1000 Spectrophotometer. The mRNAs samples from Pakistan were brought in person (by Dr. Dilshad A. Khan in dry ice to avoid any degradation of RNAs) to UMKC, Medical School after approval by (Compliance officer Mr. Christopher Winders, and Chemical/Biological Safety officer Mr. Mike Philips) members of University of Missouri Kansas City institutional review board.

The results of most important cytokines and other biomarkers associated with the present investigation were estimated by real-time RT-PCR by using plasma total RNAs purified from pre-dose versus post-dose samples after feeding δ-tocotrienol for 6-weeks to chronic hepatitis C patients has been published recently \[[@CR1]\], therefore present manuscript lacks in vitro estimations of RT-PCR data. The same plasma total RNAs were used in the present study.

The RNA-Sequence analyses were carried out at Division of Experimental and Translational Genetics, Children's Mercy Hospital, Kansas City, MO. Five randomized samples selected of total RNAs of hepatitis C patients, and combined. Total mRNAs of combined samples were purified by Biostic Blood Total RNA Isolation Kit (MOBIO Laboratories, Inc). The purified total mRNAs were further purified and concentrated to 10.0 μl by using by Gene Jet RNA Clean up and Concentration Micro Kit (Thermo Scientific, EU, Lithuania). The purity of these RNAs was further determined in the Division of Experimental and Translational Genetic & Core of Omic Research (The Children Mercy Hospital, Kansas City, MO) by their own instruments for quality control and quantity of each sample to make sure that each sample is up to standard before putting into a NGS run. The concentrated total mRNAs of each set was converted to cDNA, and total RNA-Seq carried out. Gene expression level and fold change (post vs pre-dose) of FPKM were calculated at \> 1, \> 2, or \> 5 levels at 2-fold, 4-fold, and 8-fold after filtering several million fold up-regulated and down-regulated genes (Table [1](#Tab1){ref-type="table"}).Table 1Estimation of basic RNA-sequence expresion unit (FPKM) of δ-tocotrienol treated hepatitis C patients^1^\#RNA-Seq expression unitNumber of genesGenes based on 2-foldGenes based on 4-foldGenes based on 8-fold1FPKM \> 1126149480536921362FPKM \> 2742613666965273FPKM \> 53323379285268^1^The gene expression level and fold change (post-dose vs pre-dose) of FPKM were calculated at more than 1, 2, or 5 at 2-fold, 4-fold, and 8-fold after filtering million-fold up-regulation and down-regulation. The RNA-seq analyses data based on FPKM \>1 and 8-fold change of 2136 genes (0 values were replaced with 0.001) of ratios of post-dose over pre-dose treatment of δ-tocotrienol to hepatitis C patients was submitted into "Ingenuity Pathway Analyses (IPA)" for core analysis (Ingenuity Systems, Redwood City, CA)

Statistical analyses {#Sec6}
--------------------

These data were analyzed by IPA program of treatment-mediated effects as post-dose versus pre-dose. The statistical significance level was set at 5% (*P* \< 0.05).

Results {#Sec7}
=======

Genome-wide profiling experiment of plasma mRNAs obtained from pre-dose and post-dose δ-tocotrienol treatment of hepatitis C patients {#Sec8}
-------------------------------------------------------------------------------------------------------------------------------------

The RNA-Sequence analysis was based on FPKM \> 1 and 8-fold change of 2136 genes (0 values replaced with 0.001; Table [1](#Tab1){ref-type="table"}) ratios of post-dose over pre-dose treatment of δ-tocotrienol to hepatitis C patients were uploaded into "Ingenuity Pathway Analyses (IPA)" for core analysis (Ingenuity Systems, Redwood City, CΑ). The various genes associated with different biological functions and biomarkers are from "Ingenuity Knowledge Base" generated molecular networks, according to biological as well as molecular functions. These include canonical pathways, upstream regulatory analysis, and disease-based functional network, which helped discovering the list of several biomarkers. The core analysis was carried out with the settings of indirect and direct relationship between focused molecules based on experimentally observed data and human databases in the "Ingenuity Knowledge Base" were considered as the data sources in these analyses and pathways.

"Molecules" affected by δ-tocotrienol feeding to hepatitis C patients {#Sec9}
---------------------------------------------------------------------

The IPA of "molecules section" indicates fold changes in gene expression of 953 genes, which covered several categories of biological biomarkers, which are presented in the heat-map of this section (Fig. [2](#Fig2){ref-type="fig"}). Out of these, expression of 220 genes were related to present study, and only 12 genes were up-regulated (Table [2](#Tab2){ref-type="table"}), and remaining 208 genes of various biomarkers were down-regulated after δ-tocotrienol treatment (Table [3](#Tab3){ref-type="table"}). The ceramide synthase 3 and Mohawk homeobox were only two up-regulated genes involved as transcription regulators. The down-regulated gene expression of 208 molecules are involved in several biological functions (Additional file [1](#MOESM1){ref-type="media"}: Table S1, Additional file [2](#MOESM2){ref-type="media"}: Table S2 and Additional file [3](#MOESM3){ref-type="media"}: Table S3). The functions of these regulators are ATPase NA^+^/K^+^ transporting subunit α1, apolipoprotein B, proteasome 26S subunits, NADH ubiquinone oxidoreductase subunits B1, B9, cytochrome b5 reductase 4, autophagy related 4 \~ 5, cytochrome P450 family, TNF receptor superfamily 1B, RAS P21 protein activator 2, ubiquitin conjugating enzyme B2 J1, several other types of ubiquitin proteasome subunits, and protein inhibitor of activated STAT1 (Table [3](#Tab3){ref-type="table"}). Similarly, gene regulator of G-protein signaling 2, nuclear factor of activated T-cells 2 interacting protein, TNF-α induced protein 8, C-X-C motif chemokines ligand 1, RNA polymerase II subunit H, tumor suppressor candidate 2, splicing factor 3b subunit 5, and several miRNAs (877, 1250,140), RNAs, tRNAs are reported in Table [3](#Tab3){ref-type="table"}. The summary of most important down-regulated biomarkers are HSP90AB1, IL-16, autophagy, TNFSF1B, VEGFA, NFIL3, UBP1, USP25, RASA3, USP15, UBE4A, USP19, PSMG3, IL-27RA, SCP2, IFNGR1, ID2, TUSC2, IL-1R2, IL18RP, IRF2, PCNA1250,77,40 and several tRNAs (Table [3](#Tab3){ref-type="table"}).Fig. 2Effect of several biological biomarkers in "diseases and functions" of heat map in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The fold change expression of several biological functions (hematological system, function development, cell death, survival, inflammatory response, cell to cell signaling, cancer, organism injury, organism abnormalities, cellular development and immunological diseases) are illustrated in heat mapTable 2Effect of δ-tocotrienol on up-regulation of fold change gene expression of "Molecules" section (12) of IPA analysis in hepatitis C patientsUp-regulation\#SymbolEntrez Gene NameExpr Fold ChangeType(s)1HIST1H2ADhistone cluster 1 H2A family member d1804955.068other2HHIPL2HHIP like 228.710other3RPP38ribonuclease P/MRP subunit p3824.946enzyme4CERS3ceramide synthase 319.082transcription regulator5HBG1hemoglobin subunit gamma 117.945other6MT-TQtRNA14.252other7AKR1D1aldo-keto reductase family 1 member D114.056enzyme8TSPAN15tetraspanin 1511.523other9HBG2hemoglobin subunit gamma 211.413other10MKXmohawk homeobox9.573transcription regulator12P4HA3prolyl 4-hydroxylase subunit alpha 38.686enzymeTable 3Effect of δ-tocotrienol on down-regulation of fold change gene expression of "Molecules" section (64) of IPA analysis in hepatitis C patientsDown-regulation\#SymbolEntrez Gene NameExpr Fold ChangeType(s)1ATP1A1ATPase Na+/K+ transporting subunit alpha 1-8.014transporter2HSP90AB1heat shock protein 90 alpha family class B member 1-8.049enzyme3APOBEC3Aapolipoprotein B mRNA editing enzyme catalytic subunit 3A-8.163enzyme4CXCR2C-X-C motif chemokine receptor 2-8.208G-protein coupled receptor5IL16interleukin 16-8.239cytokine6PSMC3proteasome 26S subunit, ATPase 3-8.346transcription regulator7NDUFB9NADH:ubiquinone oxidoreductase subunit B9-8.354enzyme8CYB5R4cytochrome b5 reductase 4-8.367enzyme9ATG3autophagy related 3-8.376enzyme10CREB1cAMP responsive element binding protein 1-8.452transcription regulator12NDUFB1NADH:ubiquinone oxidoreductase subunit B1-8.566enzyme13PDE3Bphosphodiesterase 3B-8.568enzyme14IGF2Rinsulin like growth factor 2 receptor-8.68transmembrane receptor15CYP2R1cytochrome P450 family 2 subfamily R member 1-8.682enzyme16NDUFA11NADH:ubiquinone oxidoreductase subunit A11-8.686enzyme17IGSF6immunoglobulin superfamily member 6-8.712transmembrane receptor18TNFRSF1BTNF receptor superfamily member 1B-8.746transmembrane receptor19PRPF18pre-mRNA processing factor 18-8.777transporter20SERP1stress associated endoplasmic reticulum protein 1-8.872other21UBE2J1ubiquitin conjugating enzyme E2 J1-8.874enzyme22VEGFAvascular endothelial growth factor A-8.933growth factor23GYS1glycogen synthase 1-9.027enzyme24GPR65G protein-coupled receptor 65-9.054G-protein coupled receptor25ILF2interleukin enhancer binding factor 2-9.105transcription regulator26OSBPL11oxysterol binding protein like 11-9.201other27PSMA5proteasome subunit alpha 5-9.31peptidase28PIAS1protein inhibitor of activated STAT 1-9.326transcription regulator29TRAF7TNF receptor associated factor 7-9.341enzyme30COX14COX14, cytochrome c oxidase assembly factor-9.447other31RPS26ribosomal protein S26-9.456other32SFPQsplicing factor proline and glutamine rich-9.469other33ATF4activating transcription factor 4-9.515transcription regulator34PECAM1platelet and endothelial cell adhesion molecule 1-9.552other35GPS2G protein pathway suppressor 2-9.56transcription regulator36NFIL3nuclear factor, interleukin 3 regulated-9.568transcription regulator37PSMB8proteasome subunit beta 8-9.709peptidase38UBP1upstream binding protein 1 (LBP-1a)-9.718transcription regulator39RAP2CRAP2C, member of RAS oncogene family-9.792enzyme40PIBF1progesterone immunomodulatory binding factor 1-9.876other41USP25ubiquitin specific peptidase 25-9.911peptidase42FRS2fibroblast growth factor receptor substrate 2-9.962kinase43PSMB4proteasome subunit beta 4-10.119peptidase44USP15ubiquitin specific peptidase 15-10.16peptidase45UBA52ubiquitin A-52 residue ribosomal protein fusion product 1-10.176enzyme46UBE4Aubiquitination factor E4A-10.189enzyme47GTPBP8GTP binding protein 8 (putative)-10.19other48USP19ubiquitin specific peptidase 19-10.713peptidase49TNFAIP8TNF alpha induced protein 8-10.974other50HSPA14heat shock protein family A (Hsp70) member 14-10.978peptidase51TLR8toll like receptor 8-11.975transmembrane receptor52IL27RAinterleukin 27 receptor subunit alpha-12.004transmembrane receptor53SCP2sterol carrier protein 2-13.672transporter54IFNGR2interferon gamma receptor 2-13.844transmembrane receptor55ID2inhibitor of DNA binding 2, HLH protein-14.133transcription regulator56TUSC2tumor suppressor candidate 2-15.922other57IL2RGinterleukin 2 receptor subunit gamma-16.787transmembrane receptor58IL1R2interleukin 1 receptor type 2-19.547transmembrane receptor59IRF2interferon regulatory factor 2-22.655transcription regulator60PTGS2prostaglandin-endoperoxide synthase 2-25.841enzyme61mir-877microRNA 877-4497.07microRNA62mir-1250microRNA 1250-4755.79microRNA63mir-140microRNA 140-5668.259microRNA64KLRC4-KLRK1/KLRK1killer cell lectin like receptor K1-1565687.642transmembrane receptor

"Causal Networks" affected by δ-tocotrienol feeding to hepatitis C patients {#Sec10}
---------------------------------------------------------------------------

The down-regulation of several biomarkers of "causal network" of IPA of RNA samples obtained after treatment with δ-tocotrienol of chronic hepatitis C patients is described in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.Table 4Effect of δ-tocotrienol on up-regulation (24) of fold change gene expression in \"causal netwworks\" section of IPA analysis in hepatitis C patients\#Master RegulatorMolecule TypePart. regulators^1^DepthPred Acti State^2^Act. Z-Score^3^*P*-Value Over^4^Network Bi-Corr^5^Causal Net^6^Target-Con-Re^7^AUp-regulation1leuprolidebiologic drug26s Proteasome,AKT13Activated2.1048.5E-100.0032217 (71)692HLA-DRcomplex26s Proteasome,AR,ATR3Activated5.4583.44E-090.0145260 (87)863PRDX1enzyme26s Proteasome,ABL13Activated7.0841.73E-080.0427250 (76)754alefaceptbilologic drugalefacept, AP1,CD23Activated2.2782.50E-070.022285 (20)205juglonechemical toxicantCASP3,FOS,juglone,JUN2Activated2.4490.000006820.027254 (9)96mir-148microRNAmir-1481Activated2.0000.001030.00554 (1)1726s Proteasomecomplex26s Proteasome1Activated2.8400.001670.047615 (1)18mir-122microRNAmir-1221Activated3.3170.001890.02211 (1)19mir-19microRNAmir-191Activated2.2360.0020.01855 (1)110mir-9microRNAmir-91Activated2.0000.004730.02034 (1)111IL2RGtransmembraneIL2RG1Activated0.0000.001810.01888 (1)112miR-2682-5p (other miRNAs w/seed AGGC)mature microRNAmiR-2682-5p (miRNAs)1Activated1.4140.005840.00732 (1)113alpha-tocopherol succinatechemical drugalpha-tocopherol succinate1Activated0.0000.005970.03164 (1)114mir-199microRNAmir-1991Activated1.7320.008490.02583 (1)115mir-138microRNAmir-1381Activated1.4140.01130.02392 (1)116miR-330-5p (other miRNAs w/seed CUCU)mature microRNAmiR-330-5p (and other1Activated1.4140.01130.02092 (1)117mir-326microRNAmir-3261Activated1.4140.01130.01912 (1)118mir-32microRNAmir-321Activated1.4140.01130.03042 (1)119LAMP2enzymeLAMP21Activated0.0000.01130.02512 (1)120mir-218microRNAmir-2181Activated1.7320.01830.03983 (1)121UBA7enzymeUBA71Activated1.4140.01830.04162 (1)122miR-147a (miRNAs w/seed UGUGUGG)mature microRNAmiR-147a (other miRNAs)1Activated1.0000.04480.04171 (1)123miR-504-5p (other miRNAs w/seed GACC)mature microRNAmiR-504-5p (miRNAs)1Activated1.0000.04480.04171 (1)124BI 2536chemical drug26s Proteasome,ABL13Activated1.3312.06E-120.0034249 (50)49^1^Part. Regulators = Paticipating Regulators; ^2^Pred Acti state = Predicted Acitivation State; ^3^Act. Z-Score = Activation Z-Score; ^4^*P*-Value Over. = *P*-Value Overlap; ^5^Network Bi-Corr = Network Bias-Corrected *P*-Values; ^7^Target-Con-Re. = Target Connected regulatorsTable 5Effect of δ-tocotrienol on down-regulation (74) of fold change gene expression in \"causal netwworks\" section of IPA analysis in hepatitis C patients\#Master RegulatorMolecule TypePart. regulators^1^DepthPred Acti State^2^Act. Z-Score^3^*P*-Value Over^4^Network Bi-Corr^5^Causal Net^6^Target-Con-Re^7^BDown-regulation25JAK1/2group26s Proteasome,Akt,AKT13Inhibited-7.5112.54E-140.0008295 (81)8026PPAR ligand-PPAR-Retinoic acid-RXRαcomplex26s Proteasome,Akt,AKT13Inhibited-4.4593.31E-130.0131306 (61)6027LXR ligand-LXR-Retinoic acid-RXRαcomplex26s Proteasome,Akt,AR3Inhibited-4.8154.17E-130.0085290 (58)5728PPARγ ligand-PPARγ-Retinoic acid-RARαcomplex26s Proteasome,Akt,AKT13Inhibited-4.2304.23E-130.0121306 (66)6529PXR ligand-PXR-Retinoic acid-RXRαcomplex26s Proteasome,AKT13Inhibited-4.4323.33E-120.0221294 (58)5830RAR ligand-RARα-Retinoic acid-RXRαcomplex26s Proteasome,Akt,AKT13Inhibited-5.3963.52E-120.039297 (57)5631Vegf Receptorgroup26s Proteasome,ABL1,Akt3Inhibited-5.0561.56E-110.0052276 (93)9032FXR ligand-FXR-Retinoic acid-RXRαcomplex26s Proteasome,Akt,AKT13Inhibited-5.1001.96E-110.0484291 (56)5533hydrogen sulfidechemical - endogenous mammalian26s Proteasome,Akt,AKT13Inhibited-4.2222.15E-110.0013237 (92)8934NLKkinase26s Proteasome,AKT1,Alp3Inhibited-3.4298.72E-110.0375248 (50)4535CD80transmembrane receptorCD28,CD80,IFNG,IL42Inhibited-6.2671.32E-100.003132 (8)836Pdgfra-Pdgfrbcomplex26s Proteasome,AKT1,AR3Inhibited-7.8781.37E-100.0184285 (93)8937Klra7 (includes others)transmembrane receptor26s Proteasome,Akt,AR3Inhibited-7.4451.44E-100.0324291 (93)9338FLT4transmembrane receptor26s Proteasome,Akt,AR3Inhibited-5.0201.46E-100.0177280 (80)7839Vegfr dimercomplex26s Proteasome,AKT1,AR3Inhibited-7.0711.59E-100.0178242 (61)5840lipopolysaccharidechemical druglipopolysaccharide1Inhibited-7.6682.75E-100.0045120 (1)141TEKkinase26s Proteasome,ADRB23Inhibited-4.9543E-100.0124274 (93)9342LATS1kinase26s Proteasome,ARID4A3Activated4.6803.43E-100.0322250 (56)5443NYAP1other26s Proteasome,Akt,AKT13Inhibited-6.2643.54E-100.0304281 (86)8544MYO16other26s Proteasome,Akt,AKT13Inhibited-6.2643.54E-100.0304281 (86)8545NYAP2other26s Proteasome,Akt,AKT13Inhibited-6.2643.54E-100.0304281 (86)8546IRSgroup26s Proteasome,ADRB23Inhibited-5.5481.63E-090.0456269 (77)7447FAK-Srccomplex26s Proteasome,ABL1,Akt3Inhibited-6.8392.41E-090.043273 (90)8648Plkgroup26s Proteasome,Akt,AKT13Inhibited-2.5002.77E-090.0425219 (55)5049G-protein betagroup26s Proteasome,ADORA2A3Inhibited-5.6473.22E-090.0309283 (103)9950ADRA1BG-protein coupled receptor26s Proteasome,ADRA1B3Inhibited-6.2384.49E-090.0406278 (86)8551IL2cytokineIL21Inhibited-4.6198.23E-090.000448 (1)152propolisbiologic drug26s Proteasome,AKT13Inhibited-2.8291.78E-080.0482231 (76)7353exenatidebiologic drug26s Proteasome,Akt,AMPK3-1.4322.36E-080.0088236 (88)8854imidazolechemical - endogenous mammalian26s Proteasome,ADORA2A31.0912.79E-080.05243 (75)7055LETM1otherAkt,AMPK,APP,AR3-1.0230.0000000690.036215 (64)6356IL-2RcomplexIL-2R,IL2RA,IL2RG,JAK12Inhibited-3.4910.000000120.010384 (14)1357IL23complexIL12B,IL23,JAK2,MTOR2Inhibited-7.1550.0000001650.011280 (9)958IL15cytokineIL151Inhibited-2.1210.0000005510.000932 (1)159TH17 CytokinegroupIL17A,IL21,IL22,TH172Inhibited-4.3230.0000008130.003739 (4)460IL4Rtransmembrane receptorIL4,IL4R,IRS1,IRS2,JAK2Inhibited-4.5030.000001020.025275 (13)1261IL21cytokineIL211Inhibited-2.9850.000005270.002822 (1)162SATB1transcription regulatorSATB111.5280.000006690.001121 (1)163cyclosporin Abiologic drugcyclosporin A11.4410.00001080.016339 (1)164IL12RB2transmembrane receptorIL12 (family),IL12RB22Inhibited-4.1160.00002330.010334 (4)365mir-26microRNAAkt,mir-2620.1920.00002470.012627 (2)266mir-221microRNAAkt,mir-2212-0.1920.00002470.012927 (2)267IL5cytokineIL51Inhibited-4.9140.00005410.013628 (1)168ropivacainechemical drugAkt,NOS3,Pkc(s)2-1.0290.00005440.028934 (5)469UCP3transporterIRS1,IRS2,PI3K2-1.9610.00006570.023126 (4)370AIF1otherAIF1,Akt,BAD2-1.1770.00006570.021126 (3)371IFN BetagroupIFN Beta1Inhibited-2.1380.000820.04314 (1)172PDGFDgrowth factorPDGFD1-0.5770.0008380.00443 (1)173PARP9enzymePARP91Inhibited-2.2360.001230.00735 (1)174PPP1R14BphosphatasePPP1R14B1-1.7320.001620.0053 (1)1^1^Part. Regulators = Paticipating Regulators; ^2^Pred Acti state = Predicted Acitivation State; ^3^Act. Z-Score = Activation Z-Score; ^4^*P*-Value Over. = *P*-Value Overlap; ^5^Network Bi-Corr = Network Bias-Corrected *P*-Values; ^7^Target-Con-Re. = Target Connected regulators

There were 676 gene regulators identified in this section, and only 98 regulators were associated with present study, indicating significant *P*-values for all regulators (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The fold change gene expression of 24 was up-regulated (Table [4](#Tab4){ref-type="table"}) and 74 down-regulated (Table [5](#Tab5){ref-type="table"}). This section includes down-regulated gene expression of 26S proteasomes, interleukin cytokines, and PPAR-ligand-PPA-Retinoic acid-RXTα, PPARγ-ligand-PPARγ-Retinoic acid-RARα, IL-7R, CD80, IRS, IL-2, IL-2RG, IL-5, IL-15, IL-21, IL-23 and several types of microRNAs (miRNAs) as shown in Table [5](#Tab5){ref-type="table"}. The activation Z-Score, *P*-values, network bias-corrected and causal network values were in descending order of all these gene biomarkers (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).

"Diseases and functions" affected by δ-tocotrienol feeding to hepatitis C patients {#Sec11}
----------------------------------------------------------------------------------

The IPA of RNAs obtained from effect of δ-tocotrienol treatment of chronic hepatitis C patients on relative percentage relationship of gene regulators (70) of "diseases and functions" reported in Table [6](#Tab6){ref-type="table"}. In this section, percentage relationships of main regulators were AP1, cAMP, EIF2AK2 2RL1, IL-17A, IL-1RN, KITLG, miRNA-155-5p, STAT2 (48%; 43/90), 26S proteasome, CSF1, IFNG, IL-17A, IRF4, LDL, RELA, TGFA (43%; 17/40); mir-223 (0%; 0/2), IL-15 (100%; 1/1), IL-1Β (0%; 0/1), and miR-21-5p (100%; 1/1) (Table [6](#Tab6){ref-type="table"}). The consistency score of these regulators varied from 1.73 \~ 36.34, total regulars (1--9), total node (5--57), diseases and functions total varied 1--10 as shown in Table [6](#Tab6){ref-type="table"}.Table 6Effects of δ-tocotrienol treatment on \"Regulator Effects\" section (70) of IPA analysis of \"Diseases and Functions\" in hepatitis C patientsIDConsistencyNodeRegulatorRegulatorsTargetDisease &Diseases & FunctionsKnown Regulator-Disease/ScoreTotalTotalTotalFuunctions TotalsFunction Relationship136.338579Ap1,CAMP,EIF2AK2,IL17A,IL1R,miR-155-5,STAT23810activation of phagocytes48% (43/90)232.199691326s Proteasome,ANGPT2,Ap1,BCL2,CAMP,CEBPA,TGFA4511activation of antigen presenting cells40% (57/143)330.414571226s Proteasome,CAMP,CSF1,F2RL1,IL17A,miR-21-5p,TGFA378activation of myeloid cells32% (31/96)430.3759713Ap1,CAMP,CCL5,EIF2AK2,F2RL1,FGF10,IL17A,6420accumulation of l cells,leukopoiesis38% (99/260)528.605561026s Proteasome,BCL2,CAMP,STAT3,TGFA,TGM2379adhesion of blood cells36% (32/90)625.45649826s Proteasome,F2RL1,IL1RN,IRF4,KLF3,STAT3,TGFA,329adhesion of immune cells26% (19/72)725.12612720ANGPT2,Ap1,CAMP,CST5,ETS1,F2RL1,IFNL1,IGF1,IL17A,9215cell movement of granulocytes40% (121/300)824.8253826s Proteasome,BCL2,CSF1,F2RL1,IL1RN,STAT3,TGFA,387adhesion of blood cells41% (23/56)923.333507CAMP,F2RL1,IL17A,mir-10,NRG1,TGFA,Tlr367cell viability of tumor cell lines63% (31/49)1023.02636726s Proteasome,BCL2,CREB1,F2RL1,IFNA2,IL1RN,TGFA227binding of leukocytes24% (12/49)1122.687551126s Proteasome,Calcineurin protein(s),CD38,EIF4E,F2RL1,377migration of macrophages23% (18/77)1221.651235CIITA,EBI3,IL27,PARP9,PDCD1126activation of lymphatic system cells53% (16/30)1321.355416F2RL1,IL1RN,miR-155-5p (miRNAs w/seed UAAUGCU),287cell viability of mononuclear leukocytes36% (15/42)1420.788425F2RL1,IL1RN,Pkc(s),TNFSF11,VEGFA289adhesion of immune cells47% (21/45)1520.715507BTNL2,CIITA,Ifn,Ifnar,IL27,SYVN1,TGM23310activation of leukocytes20% (14/70)1619.856548Ap1,CAMP,CSF2,EIF2AK2,F2RL1,IL1RN,miR-155-5p397chemotaxis of granulocytes38% (21/56)1719.73303CAMP,miR-155-5p (miRNAs w/seed UAAUGCU),PSMD10198cell death of connective tissue cells33% (8/24)1819.1508F2,F2RL1,IL17A,MIF,mir-1,PPRC1,REL,TGFA357cell viability of lymphatic system cells46% (26/56)1918.7646713Ap1,BCR (complex),CAMP,CSF2,IL12 (complex),IL21,STAT1,486synthesis of reactive oxygen species41% (32/78)2018.475417F2RL1,IL17A,LDL,mir-1,PPRC1,REL,RELA277cell viability of mononuclear leukocytes39% (19/49)2118.429758CCL5,F2RL1,IL1RN,miR-155-5pPSMD10,STAT4,TGFA4918apoptosis of fibroblast cell lines31% (45/144)2217.098346F2RL1,Igm,IL1RN,IL6,STAT3,VEGFA235binding of myeloid cells37% (11/30)2316.585337CEBPA,EGF,FLT3LG,IL17A,MIF,mir-1,REL215NK cell proliferation37% (13/35)2416.44507CAMP,F2RL1,IL17A,JUN,LDL,NRG1,TGFA376activation of antigen presenting cells,50% (21/42)2515.167507CAMP,ETS1,F2,F2RL1,IL17A,MIF,TGFA367accumulation of cells55% (27/49)2614.73252826s Proteasome,CSF1,IFNG,IL17A,IRF4,LDL,RELA,TGFA395chemotaxis of kidney cell lines43% (17/40)2714.46747526s Proteasome,AKT1,LDL,TGFA,TGM2375cellular homeostasis48% (12/25)2812.928701126s Proteasome,APP,CREB1,CSF1,IFNA2,IFNG,IL17A,TGFA545translation of mRNA44% (24/55)2912.667505CEBPA,F2RL1,IL1RN,TNFSF11,VEGFA369quantity of IgG,recruitment of cells31% (14/45)3012.33507CAMP,EIF2AK2,F2RL1,HRAS,IL17A,IL1RN,STAT2376homing of neutrophils,recruitment of cells40% (17/42)3112.221766CD40LG,GAST,miR-155-5p,TNFSF11637production of reactive oxygen species45% (19/42)3211.939326CAMP,ETS1,IL17A,KITLG,miR-155-5,miR-21-5p224infiltration by myeloid cells38% (9/24)3311.839344BTNL2,Hbb-b2,Ifnar,TRIM24246diabetes mellitus,hypersensitive reaction8% (2/24)3410.818465CEBPA,EGF,FLT3LG,IL17A,MIF356cell viability of tumor cell lines43% (13/30)359.707215F2,F2RL1,IL1RN,IL6,VEGFA133migration of antigen presenting cells60% (9/15)368.693134CD3,F2RL1,IL1RN,VEGFA72binding of myeloid cells25% (2/8)378.52122526s Proteasome,FOXO3,IL18,Pkc(s),TNFSF11152response of lymphatic system cells60% (6/10)388.01748A2M,CD40LG,GAST,mir-17,miR-17-5p,other miRNAs588anemia,binding of tumor cell lines28% (18/64)397.649365GAST,PARP9,PIK3R1,SOX4,TGFA265anemia,autophagy,organismal death16% (4/25)407.4648713CD40LG,EP300,ERG,Igm,IL7,miR-19b-3p,miR-291a-3695cell death of fibroblast cell lines28% (18/65)417.181146CSF2,EDN1,F2,IL1B,KITLG,SPI171migration of granulocytes33% (2/6)426.791265EDN1,F2,PRKCA,TNFSF11,VEGFA174Nephritis,synthesis of eicosanoid40% (8/20)436.633173IRF5,miR-155-5p (miRNAs w/seed UAAUGCU),PSMD10113apoptosis of connective tissue cells0% (0/9)446.379183ETS1,GFI1,PRL132quantity of hematopoietic progenitor cells100% (6/6)456.306223miR-155-5p (miRNAs w/seed UAAUGCU),miR-21-5p172cell death of connective tissue cells17% (1/6)466.183273CREB1,IFNA2,PDCD1222activation of leukocytes67% (4/6)475.667141GFI194HIV infection,proliferation of blood cells75% (3/4)485.345191IL5144inflammation of body cavity50% (2/4)495.292344CAMP,CSF2,IFNG,IL12 (complex)282synthesis of leukotriene75% (6/8)504.907173EGF,PRDM1,SMARCA4122endocytosis,phagocytosis of cells17% (1/6)514.276182GFI1,Pkc(s)142differentiation of mononuclear leukocytes50% (2/4)524.199373IL2,IL21,IL4304apoptosis of connective tissue cells42% (5/12)534.16173CAMP,CSF1,Immunoglobulin131mobilization of Ca2+67% (2/3)543.889122mir-8,miR-92a-3p (and other miRNAs w/seed AUUGCAC)82cell cycle progression0% (0/4)553.1381FOXO152hyperplasia of lymphoid organ,0% (0/2)563.024113Igm,Interferon alpha,STAT171apoptosis of kidney cell lines0% (0/3)573133CEBPA,IFN Beta,mir-22391production of protein33% (1/3)582.23681mir-22352Bacterial Infections,production of protein0% (0/2)591.78971E2F151cell death of fibroblasts100% (1/1)601.78971IL1551cytotoxicity of natural killer cells100% (1/1)611.78971IL1B51binding of lymphatic system cells100% (1/1)621.73251CD2831hyperplasia of lymphoid organ0% (0/1)631.508131TP53111catabolism of protein100% (1/1)640.802172HRAS,TCR141expression of mRNA0% (0/2)650.577324IFNA2,IRF7,TGFB1,TNF271systemic lupus erythematosus25% (1/4)66-2.714131IL4111infection of cells100% (1/1)67-4.08281miR-21-5p (and other miRNAs w/seed AGCUUAU)61cell death100% (1/1)68-6.561TCF7L241apoptosis of fibroblast cell lines0% (0/1)69-16.74351TRAP131synthesis of reactive oxygen species100% (1/1)70-23.519581APP561cancer100% (1/1)

"Upstream analysis" affected by δ-tocotrienol feeding to hepatitis C patients {#Sec12}
-----------------------------------------------------------------------------

The most interesting results of present IPA was "upstream analysis" of δ-tocotrienol treated hepatitis C patients. There were 934 gene regulators identified in this section. The 57 genes regulator correspond to present study were up-regulated (Table [7](#Tab7){ref-type="table"}), and 64 gene regulators down-regulated (Table [8](#Tab8){ref-type="table"}). There were several miRNAs (38), which were up-regulated and remaining other important biomarkers gene were down-regulated (Table [8](#Tab8){ref-type="table"}). The activation Z-Scores (3.79--1.26) and *P*-values (5.39E-8 -- 1.26) were significant from each biomarkers. The down-regulated biomarkers included several cytokines (IL-2, Il-5, IL-6, IL-7, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-21, IL-24, IL-27, IL-32), as well as miRNA-15, miRNA-124, miRNA-218-5P, interferon β-1a, interferon γ, TNF-α, STAT2, NOX1, prostaglandin J2, NF-κB, IκB, and TCF3 (transcription regulator), with significant activation Z-Score (− 4.56--2.531), and *P*-values were 9.17--14.00; *P* \< 0.05, respectively (Table [8](#Tab8){ref-type="table"}).Table 7Effect of δ-tocotrienol on up-regulation of fold change expression in "upstream regulator" section (57) of IPA analysis in hepatitis C patientsUpstream RegulatorMolecule TypePredicted Activation StateActivation Z-Score*P*-value of overlapMechanistic Network\#Up-regulated1miR-17-5p (and other miRNAs w/seed AAAGUGC)mature micrornaActivated3.7985.39E-08127 (7)2miR-155-5p (miRNAs w/seed UAAUGCU)mature micrornaActivated4.5189.04E-06137 (7)3miR-19b-3p (and other miRNAs w/seed GUGCAAA)mature micrornaActivated2.1980.000174miR-92a-3p (and other miRNAs w/seed AUUGCAC)mature micrornaActivated2.1870.007445miR-214-3p (and other miRNAs w/seed CAGCAGG)mature microrna0.01136miR-291a-3p (and other miRNAs w/seed AAGUGCU)mature micrornaActivated2.9940.0177miR-21-5p (and other miRNAs w/seed AGCUUAU)mature micrornaActivated2.5950.01598miR-330-5p (and other miRNAs w/seed CUCUGGG)mature microrna0.01139miR-122-5p (miRNAs w/seed GGAGUGU)mature micrornaActivated2.5860.027910miR-2682-5p (and other miRNAs w/seed AGGCAGU)mature microrna0.0058411miR-205-5p (and other miRNAs w/seed CCUUCAU)mature microrna0.032512miR-200b-3p (and other miRNAs w/seed AAUACUG)mature microrna1.9600.027313miR-542-3p (miRNAs w/seed GUGACAG)mature microrna0.036314miR-221-3p (and other miRNAs w/seed GCUACAU)mature microrna1.9570.034915miR-147a (miRNAs w/seed UGUGUGG)mature microrna0.044816miR-450a-5p (and other miRNAs w/seed UUUGCGA)mature microrna0.044817miR-216a-5p (miRNAs w/seed AAUCUCA)mature microrna0.044818miR-504-5p (and other miRNAs w/seed GACCCUG)mature microrna0.044819miR-657 (miRNAs w/seed GCAGGUU)mature microrna0.044820mir-17micrornaActivated2.5810.0009121mir-122micrornaActivated3.3000.0018922mir-19micrornaActivated2.2040.00223mir-1micrornaActivated2.720.00354128 (6)24mir-214microrna0.0090625mir-326microrna0.011326mir-138microrna0.011327mir-32microrna0.011328mir-155microrna1.9650.00691173 (8)29mir-148microrna1.9970.0010330mir-199microrna0.0028164 (7)31mir-218microrna0.018332mir-515microrna0.022533mir-132microrna0.034934mir-10micrornaActivated2.7860.036635mir-8micrornaActivated2.1280.034436mir-25microrna1.9720.034937mir-622microrna0.044838mir-181microrna0.9880.049839ImmunoglobulincomplexActivated2.3450.00024283 (16)40prednisolonechemical drug1.7630.00025235 (13)4126s ProteasomecomplexActivated2.9210.000933326 (16)42IgGcomplex1.0030.00824295 (16)43TRAP1enzymeActivated2.2360.016944IL1RNcytokineActivated3.2350.027545prostaglandin A1chemical - endogenous non-mammalian0.6860.00249159 (8)46AGTR1g-protein coupled receptor1.0670.029147MAPK1kinase1.0170.036148Ubiquitingroup0.03949IL18RAPtransmembrane receptor0.036350TAB1enzyme1.2580.034951eIF2Bcomplex0.044852SNRPNother0.044853SNORD21other0.044854SOS2other0.044855IL1RL2transmembrane receptor0.046956IL18BPother0.046957IL10RAtransmembrane receptorActivated2.6880.229Table 8Effect of δ-tocotrienol on down-regulation of fold change expression in "upstream regulators" section (64) of IPA analysis in hepatitis C patients\#Upstream RegulatorMolecule TypePredicted Activation StateActivation z-score*p*-value of overlapMechanistic NetworkDown-regulated1interferon beta-1abiologic drug9.17E-142IL2cytokineInhibited-4.5622.23E-09297 (17)3IL15cytokineInhibited-2.2471.37E-08299 (19)4FAStransmembrane receptor-1.4613.94E-08263 (17)5TNFcytokineInhibited-5.9140.000000294378 (19)6IL21cytokineInhibited-2.7470.00000339264 (15)7GATA1transcription regulator-0.8220.00000497243 (11)8IRF1transcription regulatorInhibited-3.2230.000011245 (13)9EGFgrowth factorInhibited-5.150.0000204303 (15)10TGFB1growth factorInhibited-3.4910.00004350 (17)11IL6cytokineInhibited-3.0430.0000566284 (15)12IL5cytokineInhibited-4.8660.0000654243 (13)13Interferon alphagroupInhibited-4.0690.000154150 (9)14STAT4transcription regulatorInhibited-4.5360.000489111 (6)15IL7cytokineInhibited-2.6650.00064243 (18)16IL13cytokine-1.5160.000806295 (16)17STAT1transcription regulatorInhibited-4.5820.000877241 (14)18IL1BcytokineInhibited-4.3670.000982330 (17)19STAT2transcription regulatorInhibited-2.2190.00105173 (9)20PARP9enzymeInhibited-2.2000.00123142 (6)21FOXC1transcription regulator-1.9610.00222IL2RGtransmembrane receptor-0.1130.0023323IL12 (complex)complexInhibited-2.3780.00251246 (17)24TGFAgrowth factorInhibited-2.8880.00327283 (17)25CD14transmembrane receptor-1.7680.00332298 (16)26TNFSF10cytokine-1.3760.00477297 (17)27mir-223micrornaInhibited-2.0600.00527167 (7)28IL27cytokineInhibited-2.9370.00527317 (16)29beta-estradiolchemical - endogenous mammalianInhibited-4.5740.00546358 (17)30IL10cytokine-0.8030.00582247 (17)31ADORA2Ag-protein coupled receptorInhibited-2.3650.00599175 (9)32IFNL1cytokineInhibited-2.9250.00622224 (11)33IL18cytokineInhibited-2.260.00701326 (19)34NOX1ion channel-1.9510.00741263 (14)35SOX4transcription regulatorInhibited-3.0330.0083436prostaglandin J2chemical - endogenous non-mammalian-1.4320.011537E2F1transcription regulatorInhibited-2.0810.014238CREB1transcription regulatorInhibited-3.7660.014339IGF1growth factorInhibited-2.3850.015840IL12 (family)group-0.5000.01641IRF5transcription regulatorInhibited-2.1550.016242FOXO4transcription regulator-1.980.017943PGFgrowth factor-1.9590.023744BTG2transcription regulator1.1650.023945mir-15microrna-0.9270.027946STAT5Atranscription regulator-0.8960.029447NFE2L2transcription regulatorInhibited-3.6440.029548MIFcytokineInhibited-2.6420.030449FGF10growth factorInhibited-2.2000.030550miR-26a-5p (and other miRNAs w/seed UCAAGUA)mature microrna1.9160.030951NOX4enzyme-1.9410.030952NFKBIBtranscription regulator-1.4000.033153IFNA1/IFNA13cytokine-1.770.033154FLT3LGcytokineInhibited-2.4110.033155IL17Fcytokine-1.9170.034956IL32cytokine-1.150.041657CCL5cytokineInhibited-2.6210.04258IL17AcytokineInhibited-3.0750.042259MIR124group1.9410.043560miR-218-5p (and other miRNAs w/seed UGUGCUU)mature microrna0.044361CXCR4g-protein coupled receptor-0.8420.044762CD38enzymeInhibited-3.4290.048263IL24cytokine-0.2770.049864TCF3transcription regulatorInhibited-2.5300.231

"Diseases or functions annotation" affected by δ-tocotrienol feeding in hepatitis C patients {#Sec13}
--------------------------------------------------------------------------------------------

The effect of δ-tocotrienol on gene expression in "diseases or functions annotation" of IPA of mRNAs sample of chronic hepatitis C patients resulted in determining 500 types of diseases and functions. Out of these 11 type genes of diseases and functions were up-regulated, while 49 were down regulated (Table [9A](#Tab9){ref-type="table"} and [B](#Tab9){ref-type="table"}). The up-regulated genes (11) of functions include cell death/survival cell death, organismal injury and abnormalities, cellular function and maintenance, gene expression, protein synthesis, metabolic disease, and neurological diseases as shown in Table [9A](#Tab9){ref-type="table"}. Their *p*-values and activation Z-Scores varied from 3.94E21--8.54E6 2.64--0.71 (***P*** \< 0.01), respectively (Table [9A](#Tab9){ref-type="table"}). The gene expression of 49 were down-regulated after δ-tocotrienol treatment of chronic hepatitis C patients. These genes are involved in cellular development, cellular growth, proliferation hematology, infectious diseases, cell-to-cell signaling/interaction, cardiovascular disease, antimicrobial response, cell morphology, inflammatory response, neurological disease, humoral immune response, free radical scavenging, immunological diseases, lipid metabolism, gene expression, cancer, RNA post-transcriptional modification and many other diseases as outlined in Table [9B](#Tab9){ref-type="table"}.Tables 9Effect of δ-tocotrienol on \"diseases or functions annotation\" section of IPA analysis of total mRNAs of hepatitis C patients\#CategoriesDiseases or Functions Annotation*P*-ValuePredicted ActivationAct Z-ScoreMolecules\# MoleculesAUp-regulated (11)1Cell Death and Survivalcell death3.94E-21Increased2.645ABCD1,ABL1,ACO23492Cancer, Cell Death and Survivalnecrosis of malignant tumor4.75E-21Increased3.412ABL1,B2M,BCL2L11763Cellular Function and Maintenancefunction of lymphatic system cells2.1E-160.273ABL1,ARHGEF,604Cellular Function and Maintenancefunction of leukocytes1.25E-150.051ARHGEF6,ARRB2,B2M775Gene Expression, Protein Synthesistranslation of mRNA1.6E-12Increased2.941BTG2,DNAJC1,EIF2S3366Gene Expressionexpression of mRNA3.44E-12Increased2.115BTG2,CD47,DNAJC1437Metabolic Diseaseglucose metabolism disorder2.76E-081.558ABHD16A,ALOX5AP,ANAPC131368Organismal Survivalorganismal death0.00000495Increased11.544ABL1,ADORA2A,APRT2109Cancer, Hematological Diseaselymphoproliferative malignancy0.000005921.725ABL1,ADORA2A,AIMP120310Neurological Disease, Organismaldisorder of basal ganglia0.00007811.538ABCD1,ABL1,ADORA2A7611Cancer, Organismal Injurycarcinoma0.00008540.711ABCD1,ABHD16A,ABL1749BDown-regulated (49)12Cellular Development, Cellularproliferation of immune cells1.29E-24Decreased-2.128ABL1,ADORA2A,ARHGEF612813Cellular Development, Cellularproliferation of mononuclear leukocytes6.29E-24Decreased-2.073ABL1,ADORA2A,ARHGEF612314Infectious DiseasesViral Infection6.4E-24Decreased-5.928ABL1,ADORA2A,AGO420715Cellular Growth and Proliferationproliferation of lymphatic system cells8.63E-24Decreased-2.019ABL1,ADORA2A,ARHGEF612916Immunological Diseasesystemic autoimmune syndrome2.37E-23-0.774ABHD16A,ADORA2A,AKR1D116317Hematological System Developmentquantity of mononuclear leukocytes6.64E-19Decreased-4.691ABL1,ADORA2A,ARHGEF611318Lymphoid Tissue Structurequantity of lymphatic system cells1.46E-18Decreased-4.679ABL1,ADORA2A,ARHGEF611519Hematological System Developmentquantity of blood cells6.22E-16Decreased-4.724ABL1,ADD3,ADORA2A13420Cell-To-Cell Signaling and Interactionactivation of cells2E-15Decreased-5.698ADORA2A,AFP,ARRB212721Connective Tissue Disordersinflammation of joint2.16E-13-1.573ABL1,ADORA2A,AKR1D112822Cardiovascular Disease, DevelopmentalDiamond-Blackfan anemia4.55E-11CD52,FLVCR1,RPL111323Antimicrobial Response, Inflammatoryantimicrobial response8.55E-09-1.395APOBEC3A,ATG5,BCL104424Embryonic Development, Hematologicalformation of lymphoid tissue1.45E-08Decreased-2.618ABL1,B2M,BCL2L114825Free Radical Scavengingmetabolism of reactive oxygen species1.56E-08Decreased-2.89ABL1,ATG5,ATP7A6326Neurological Disease, Skeletalneuromuscular disease5.12E-07-0.200ABL1,ADORA2A,ALAS19527Cell Morphologymorphology of blood cells7.37E-07ABCD1,ABL1,ADD35228Inflammatory Response, Neurologicalinflammation of central nervous system0.00000109-1.099ADORA2A,B2M,C3AR14829Humoral Immune Response, Proteinproduction of antibody0.00000114-1.497B2M,BCL10,BCL2L114030Endocrine System Disordersdiabetes mellitus0.00000166Decreased-2.058ABHD16A,ALOX5AP,ANAPC1311031Digestive System Developmentmorphology of Peyer\'s patches0.00000208DDX58,ID2,IGKC1232Cellular Compromise, Inflammatorydegranulation of cells0.0000021Decreased-3.08C3AR1,C5AR1,CAMP3133Cell Signaling, Molecular Transportmobilization of Ca2+0.00000212Decreased-2.95ADORA2A,ARRB2,B2M4234Cell-To-Cell Signaling and Interactionbinding of leukocytes0.00000273Decreased-4.799ABL1,ADORA2A,ARRB24635Immunological Diseaseallergy0.00000286-1.655ABL1,ACO2,ADORA2A4936Humoral Immune Response, Proteinquantity of immunoglobulin0.00000494-1.731B2M,BCL10,BCL2L113737RNA Post-Transcriptional Modificationprocessing of RNA0.0000059-0.670ADAT1,AFF2,CELF13638Hematological System Developmentquantity of thymocytes0.00000592Decreased-3.599ABL1,B2M,BCL103039Immunological Diseaseabnormal morphology of immune0.00000593ABCD1,ABL1,B2M3740Cancer, Hematological Diseasemature B-cell lymphoma0.00000888ABL1,B2M,BCL103841Digestive System Developmentabnormal morphology of Peyer\'s0.00000906DDX58,ID2,IGKC1142Lipid Metabolism, Small Moleculesynthesis of eicosanoid0.00000989Decreased-3.209ALOX5AP,ATP5J,C5AR12943Cellular Growth and Proliferationexpansion of cells0.0000113-0.717ADORA2A,B2M,BMI13744Lipid Metabolism, Small Moleculesynthesis of leukotriene C40.0000148Decreased-2.753ALOX5AP,C5AR1,COTL1845Gene Expressionactivation of DNA endogenous0.000016Decreased-3.846ARRB2,ATF4,BMI111146Antigen Presentation, Inflammatoryantigen presentation0.0000715-1.556ARL8B,CD74,CST31447Cell Death and Survival, Organismalcell death of kidney cells0.0000715-1.863ATG5,ATP1A1,BCL103948Cellular Movement, Hematologicalchemotaxis of granulocytes0.0000723Decreased-2.235ADORA2A,BST1,C3AR12449Cancer, Hematological Diseaselarge-cell lymphoma0.0000741B2M,BCL2L11,CAMLG3450Cell-To-Cell Signaling and Interactionbinding of mononuclear leukocytes0.0000753Decreased-3.212CD47,CD48,CD582551Cellular Movement, Embryonicchemotaxis of embryonic cell lines0.0000767Decreased-2.587ARRB2,CAMP,CXCL1752Cellular Movement, Hair and Skinchemotaxis of epithelial cell lines0.0000767Decreased-2.587ARRB2,CAMP,CXCL1753Cell Death and Survival, Skeletalcell death of smooth muscle cells0.0000775-0.332ARRB2,CAMP,CASP31654Cell Death and Survivalcell viability of phagocytes0.0000775Decreased-2.939BCL2A1,CD48,CEBPB1655Cell Death and Survivalkilling of lymphatic system cells0.0000789Decreased-2.016BCL2L11,CD47,CD481056Cell Death and Survivalcell viability of mononuclear leukocytes0.0000805Decreased-3.491ATG3,BCL10,BCL2L112557Cellular Development, Cellular Growthdifferentiation of myeloid leukocytes0.0000809-1.081ABL1,CAMP,CD473158Cell-To-Cell Signaling and Interactionbinding of lymphatic system cells0.0000847Decreased-3.360CD47,CD48,CD582359RNA Post-Transcriptional Modificationunwinding of mRNA0.000086EIF4A1,EIF4A2,EIF4B360Cell Death and Survival, Organismalcell death of epithelial cells0.000136-1.105ARRB2,ATG5,BCL1051

The results described so far are summarized in Table [10](#Tab10){ref-type="table"}. The data were divided into 12 categories, each category has 5 topics (total 60), and out of these 60 topics, only 13 topics were further investigated in detail for their functions related to present studies. For example, the "diseases and disorder" category (III) includes infectious diseases, immunological diseases, cancer, and organismal injury/abnormalities and tumor morphology (Table [10](#Tab10){ref-type="table"}). The "molecular and cellular functions" category (IV) includes cellular development, cellular growth and proliferation, death/survival, cell-to-cell signal ligand interaction and cellular function and maintenance. Table [10](#Tab10){ref-type="table"} also includes a list of expression log ratio of 10 up-regulated genes (SNORD15A, SNORA32, SNORA56, SNORA9, SNORA3B, SNORA3A, HIST1H2AD, LINC00305, HHIPL2), and 10 down-regulated genes (HMGN1P3, SNHG25, SNORA67, RPL17-C18orf32, ISY1-RAB43, ARHGEF18, KLRC4-KLRK1/KLRK1, HIST1H3J, MTHFS, SNORA16A) were related to present investigation. At the end, out of 360 "canonical pathways" of IPA of total mRNAs samples of effects of δ-tocotrienol treatment to hepatitis C patients, 33 pathways are selected, which are associated with various signaling and biomarkers relative to present results (Table [11](#Tab11){ref-type="table"}). The heat map (Fig. [2](#Fig2){ref-type="fig"}) also depicts same diseases and functions as outlined in Tables [9A, B](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"}.Table 10Summary of IPA analyses of RNAs obtained from δ-tocotrienol treatment of hepatitis C patients\#Subjects*P*-Value ovrlapOverlap\#Subjects*P*-Value ovrlap\# MoleculesITop Canonical PathwaysVIICardiotoxicity1EIF2 Signaling1.28E-3730.3 % 67/22131Cardiac Infarction3.62E-01 - 5.40E-04232Regulation of eIF4 and p70S6K Signaling5.38 E-14021.0 % 33/15732Caediac Necrosis/Cell Death1.65E-01 - 2.56E-03233mTOR Signaling1.28 E-1318.4 % 37/10233Cardiac Dycfunction4.31E-01 - 2.63E-03114B Cell Receptor Signaling8.35 E-0814.2 % 27/19034Cardiac Fibrosis1.77E-01 - 5.68E-03145Signaling1.72E-0616.2 % 18/11135Cardiac Transformation1.10E-02 - 1.10E-022IITop Upstream RegulatorsPredicted ActivationVIIIHepatotoxicity6ST 19265.62E-20Activated36Liver Proliferation2.15E-01 - 5.85E-05267Sirolimus2.32E-18Activated37Liver Necrosis/Cell Death6.13E-01 - 6.59E-05298CD 4371.45E-17Activated38Liver Damage4.69E-01 - 1.81E-04359RICTOR1.64E-17Activated39Liver Inflamma/Hepatitistion4.52E-01 - 5.02E-043610MYCN3.22E-15Inhibited40Liver Cirrhosis4.19E-02 - 1.65E-0321IIIDiseases and Disorder\# MoleculesIXNephrotoxicity11Infectious Diseases1.14E-04 - 1.29E-2424441Renal Necrosis/Cell Death3.32E-01 - 7.15E-054612Immunological Disease7.41E-05 - 2.37E-2337242Renal Inflammation3.74E-01 - 1.69E-033313Cancer1.25E-04 - 4.75E-2283943Renal Nephritis3.70E-01 - 1.69E-033314Organismal Injury and Abnormalities1.36E-04 - 4.75E-2186544Renal Damage5.15E01 - 3.12E-032115Tumor Morphology1.19E-04 - 4.75E-218245Glomerular Injury1.00E-00 - 1.47E-0222IVMolecular and Cellular Functions\# MoleculesXTop Regulator Effect NetworksDisease & FunctionsConsistency Score16Cellular Development1.24E-04 - 1.29E-2422246Ap1,CAMP,F2RL1,IL17A,IL1RN,KITLG,mir10,NRG1,SELP (+2 \>)Activationof antigen presenting cells (+11 \>)40.84817Cellular Growth and Proliferation1.24E-04 - 1.29E-2420647AP1,CAMP,EIF2AK2,F2RL1,IL17A,IL1RN, KITLG (+2 \>)Activationof phagocytes (+9 \>)36.33818Cell Death and Survival1.36E -04 - 3.94E-213714826s Proteasome,ANGPT2,AP1,BCL2,CAMP,CEBPA,F2RL (+6 \>)Activationof antigen presenting cells (+10 \>)32.19919Cell-To-Cell Signalingand Interaction1.34EE-18-04 - 7.041834926s Proteasome,CAMP,CSF1,IL17A,JUN,LDL (+5 \>)F2RL (+6 \>)Activationof antigen presenting cells (+7 \>)30.41420Cellular Function and Maintenance1.02E-04 - 2.10E-1623250AP1,CAMP,CCL5,EIF2AK2,F2RL1,FGF10,IL17A,IL1RN (+5 \>)Accumulation of leukocytes (+19 \>)30.375VPhysiological System Development and Function\# MoleculesXITop Networks (Associated Network Functions)Score21Hematological System Development and Function1.34E-04 -1.29E-2425551Developmentall Disorder, Hereditary Disorder, Metabolic Diseases4622Lymphoid Tissue Structure and Development1.33E-04 -1.29E-2419452Cancer, Cell Death and Survival, Organismal Injury and Abnormalities4423Tissue Morphology1.19E-04 - 2.45E-1918453Post-Translational Midification, Cell Cycle, Cellular Development4424Immune Cell Trafficking1.34E-04 - 7.04E-1816054Cancer, Hematological Disease, Immunological Disease4125Hematopoiesis1.02E004 - 6.87E-1413055Protein Synthesis, RNA Post-Transcriptional Modification, Gene Expression39VITop Tox Functions (Clinical Chemistry and Hematology)\# MoleculesXIITop Toxicology Lists*p*-valueOverlap26Increased Levels of Albumin2.38E-01 - 1.24E-02456Renal Necrosis/Cell Death1.58E-058.60 % 46/53827Increased Levels of Alkaline Phosphatase2.12E-01 - 4,42E-02657Liver Prolification1.80E-0511.0 % 26/23628Decreased Levels of Hematocrit5.71E-02 - 5.71E-02258Liver Necrosis/ Cell Death8.35E-059.6 % 29/30329Increased Levels of Hematocrit6.20E-02 - 6,20E-02859Mechanism of Gene regulation by Peroxisome2.74E-0413.7 % 13/9530Increased Levels of Potassium5.36E-01 - 8.64E-02260Increases Liver Damage7.40E-0411.4 % 15/132AGene Expression Fold Change (Up-regulated)Expression ValueBGene Expression Fold Change (Down-regulated)Expression Value1SNORD15A581.1511HMGN1P3-381.062SNORA32390.3532SNHG25-350.05553SNORA56185.1943SNORA67-148.694SNORA9124.6984RPL17-C18orf32-67.2535SNORS3B102.915ISY1-RAB43-51.1476SNORA3A93.096ARHGEF18-41.3817HIST1H2AD20.7847KLRC4-KLRK1/KLK1-20.5788SNORD3D17.1578HIST1H3J-19.7959LINC003054.8539MTHFS-18.7110HHIPL24.84410SNORA16A-18.285Table 11Effect of δ-tocotrienol on canonical pathways (33) of IPA ingenuity canonical pathways analysis (360) in hepatitis C patients\#Ingenuity Canonical Pathways (Fold Change Expression)-log (*p*-value)RatioZ-ScoreMolecules1EIF2 Signaling; Eukaryotic translation initiation factors (221)36.9000.303-5.692RPL7A,EIF3G,RPL13A,RPL32,RPS24,RPL37A,RPL23,RPL26,RPS132Regulation of eIF4 and p70S6K signaling (157)13.3000.2100.000PPP2R5E, EIF3G, RPS263Protein ubiquitination pathway (265)3.1300.091\#NUM!UBE2J1, USP19, UBA524mTOR signaling; Mammalian target of rapamycin (201)12.9000.184-2.138PPP2R5E, EIF3G, RPS265Type I Diabetes Mellitus Signaling (111)5.7600.162-2.496NFKB1,MAP3K5,JAK2,HLA-DQB1,IFNGR2,TNFRSF1B,PIAS1,TRADD6Th1 and Th2 Activation Pathway (185)5.6400.130\#NUM!NFKB1,JAK2,NOTCH1,HLA-DQB1,IFNGR2,PIK3R1,HLA-DRA7Interferon Signaling (36)4.7000.250-2.333IFNGR1,OAS1,IFIT1,JAK2,IFITM1,IFNGR2,IFITM2,PIAS1,PSMB88Role of IL-17F (44)3.9600.205-3.000NFKB1,ATF4,CREB1,RPS6KA3,CXCL1,MAPK1,CXCL8,RPS6KA49IL-8 Signaling (197)3.3200.102-4.123NFKB1,GNA13,GNB4,RACK1,VEGFA,MYL12B,PIK3R1,ARRB2,NCF210NF-κB Signaling (181)2.9400.099-4.243GSK3B,SIGIRR,NFKB1,CSNK2B,TNFRSF1B,IL1R2,PIK3R1,TRADD11IL-17A Signaling in Fibroblasts (35)2.4000.171\#NUM!GSK3B,NFKB1,CEBPD,CEBPB,MAPK1,TRAF612IL-6 Signaling (128)2.3600.102-3.051NFKB1,JAK2,CSNK2B,TNFRSF1B,VEGFA,IL1R2,PIK3R1,CXCL8,FRS213Induction of Apoptosis by HIV1 (61)2.2800.131-2.828CXCR4,NFKB1,MAP3K5,TNFRSF1B,CASP3,TRADD,RIPK1,SLC25A1314HMGB1 Signaling (133)2.2200.098-3.606OSM,NFKB1,IFNGR2,TNFRSF1B,PIK3R1,SP1,CXCL8,IFNGR1,HMGB115PPAR Signaling (95)2.0400.1051.897NFKB1,TNFRSF1B,PTGS2,IL18RAP,MAPK1,IL1R2,HSP90AB1,SCAND116IL-10 Signaling (69)1.9600.116\#NUM!NFKB1,IL18RAP,MAPK1,IL1R2,SP1,FCGR2A,TRAF6,IL10RA17iNOS Signaling (45)1.8600.133-2.449IFNGR1,NFKB1,JAK2,IFNGR2,MAPK1,TRAF618Insulin Receptor Signaling (141)1.6500.085-1.508GSK3B,PPP1CC,PTEN,JAK2,GYS1,PDE3B,FRS2,MAPK1,GSK3A19p53 Signaling (111)1.6000.0900.000GSK3B,DRAM1,PTEN,HIF1A,FRS2,ATR,ST13,PIK3R1,PIAS1,PCNA20Role of IL-17A in Arthritis (69)1.4900.101\#NUM!NFKB1,FRS2,PTGS2,CXCL1,MAPK1,PIK3R1,CXCL821Toll-like Receptor Signaling (76)1.3000.092-1.000SIGIRR,TLR8,UBA52,NFKB1,MAP3K1,MAPK1,TRAF622IL-1 Signaling (92)1.3000.087-2.449GNAQ,NFKB1,GNA13,GNB4,RACK1,MAP3K1,MAPK1,TRAF623Apoptosis Signaling (90)0.9870.078-0.378NFKB1,MAP3K5,BCL2L11,BCL2A1,TNFRSF1B,MAPK1,CASP324PDGF Signaling (90)0.9870.078-2.646ABL1,JAK2,CSNK2B,MAP3K1,FRS2,MAPK1,PIK3R125Type II Diabetes Mellitus Signaling (128)0.9440.070-2.333NFKB1,MAP3K5,TNFRSF1B,MAP3K1,FRS2,CEBPB,MAPK1,PIK3R126IL-15 Signaling (76)0.9040.107\#NUM!NFKB1,JAK2,TXK27autophagy (62)0.8590.081\#NUM!CTSW,ATG3,ATG5,CTSC,LAMP228IL-2 Signaling (64)0.8180.078-2.000CSNK2B,FRS2,MAPK1,PIK3R1,IL2RG29PPARα/RXRα Activation (180)0.7590.0613.000TGS1,GNAQ,TGFBR2,NFKB1,JAK2,IL18RAP,MAPK1,MED12,IL1R230TNFR1 (32)2.2100.140-2.646NFKB1,MAP4K2,MAP3K1,PAK1,CASP3,TRADD,RIPK131STAT3 Pathway (74)0.6410.068-1.342TGFBR2,JAK2,MAPK1,PTPN6,IGF2R32Nitric Oxide Signaling in the Cardiovascular System (113)0.6330.062-2.646ITPR2,VEGFA,PDE3B,FRS2,MAPK1,PIK3R1,HSP90AB133Osteoarthritis Pathway (210)3.3700.100-2.524NFKB1,CREB1,NOTCH1,TNFRSF1B,VEGFA,KEF1,IL-1R2,mir-140

Discussion {#Sec14}
==========

The fold-change gene expression data analyzed by Ingenuity Pathway Analysis describes cellular and biological mechanisms at the molecular level on the effect of δ-tocotrienol in chronic hepatitis C patients. It involves metabolic and cellular processes, mainly associated with catalytic activity of structural molecules. It also reveals an insight of correlation of signaling pathways and transcriptional factors, and subsequently describes inhibition or activation of anti- and pro-inflammatory genes. The results of these functional genomics produced a huge amount of data analyzed by biological networks using differentially gene expression after treatment with δ-tocotrienol to chronic hepatitis C patients. It predicts possible canonical pathways, upstream regulators, diseases and functional metabolic networks. The differential gene expressions of several biological functions illustrated in the heat map is shown in Fig. [2](#Fig2){ref-type="fig"}.

The present data revealed that genes responsible for replication of virus, infection by RNA viruses, infection of tumor cell lines, HIV infection and replication of influenza virus were all down-regulated, while cell death processes were all up-regulated. Moreover, as mentioned earlier, that Table [10](#Tab10){ref-type="table"} includes a list of expression log ratio of 10 up-regulated and 10 down-regulated genes. The forgoing information is mainly from "Ingenuity Knowledge Base" including as the information source for these facts and pathways.

The first up-regulated gene, SNORD15 is a non-coding RNA (ncRNA) gene which involves in the modification of other small nuclear RNAs (snRNAs), located in the nucleolus of the eukaryotic cell, which is a major site of snRNA biogenesis, and known as small nuclear RNA (snoRNA) \[[@CR9]\]. It belongs to C/D box class of snoRNA, which function in directing site-specific 2-O-methylation of substrate RNAs \[[@CR9]\]. In humans, there are two closely related copies of the U15 snoRNA (called SNORD15A and SNORD15B) \[[@CR10]\]. Histone H2A type 1-D encoded by HIST1H2AD gene in humans. Histones are basic nuclear proteins that are responsible for the nucleosome structure of chromosomal fiber in eukaryotes. LINC00305 is associated with atherosclerotic plagues and monocytes \[[@CR11]\]. Overexpression of LINC00305 promoted the expression of inflammation-associated genes in THP-1cells and reduced the expression of contractile markers in co-cultured human aortic smooth muscle cells. LINC00305 overexpression activated NF-κB and inhibition of NF-κB abolished LINC00305-mediated activation of cytokine expression \[[@CR12]\]. HHIPL-2 identified as a candidate gene involved in iron-related modulation of osteoblast markers. The excess of iron limits HHIP-2 gene expression and decreases osteoblastic activity in human MG-63 cell \[[@CR13]\].

Whereas, the "High Mobility group Nucleosome Domain 1 Pseudogene 3" (HMGN1P3) is a down-regulated pseudogene 3, and belongs to NURSA nuclear receptor signaling pathways expression of HMGN1P3 gene, and involves in all type of cancers (from breast, prostate, pancreas, colon kidney, lung, ovary, uterus) \[[@CR14], [@CR15]\]. The small nuclear RNA (SNORA67) is also a down-regulated non-coding RNA molecule that belongs to the H/ACA class of snoRNA, which guide the sites of modification of uridines and pseudouridines \[[@CR16]\]. The ISY1-RAB43 is the naturally occurring read-through transcription gene, which act between the neighboring ISY1 (splicing factor homolog) and RAB43 (member RAS oncogene family) gene on chromosome 3. The read-through transcript encodes is a protein that shares sequence identity with the upstream gene product, but its C-terminus is distinct due to a frameshift relative to the downstream gene \[[@CR17]\]. The Rho/Rac guanine nucleotide exchange factor 18 (ARHGEF18) is GTP binding proteins that regulate a number of cellular functions such as, cytoskeletal rearrangements, gene transcription, cell growth and motility \[[@CR18]\].

The KLRC4-KLRK1 gene represents also naturally occurring down-regulated read-through transcription gene, which acts between the neighboring KLRK4 (killer cell lectin-like receptor subfamily C, member 4) family. This protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers \[[@CR19]\]. Histone H3.1 is a protein that in human encoded by the HIST1H3J gene \[[@CR20], [@CR21]\]. Histones are basic nuclear proteins that are responsible for the nucleosomes fiber in eukaryotes. The methenyltetrahydrofolate synthetase (MTHFS) is down- regulated encoded an enzyme that catalyzes the conversion of 5-formyltetrahydrofolate to 5, 10-methenyltetrahydrofolate, and helps regulate carbon flow through the folate-dependent one-carbon metabolic network \[[@CR22], [@CR23]\]. The small nucleolar RNA, H/ACA box 16A (SNORA16A) gene provides a unified query environment for genes defined by sequence \[[@CR24]\].

The study also provides an insight of correlation of signaling pathways and transcriptional factors and subsequently describes the modulation of anti- as well as pro-inflammatory genes. It described the effects δ-tocotrienol in chronic hepatitis C patients on gene expression of liver cancer, liver hyperplasia, cell proliferation, cell growth, cell death/survival, infections, inflammatory diseases, and apoptosis. Collectively, the effects of δ-tocotrienol on "canonical pathways" observed in IPA of total mRNA sample of hepatitis C patients resulted in modulation of over 360 pathways, which are associated with multiple signaling pathways. It is conceivable that some or most of these pathways may be controlled by the proteasome, since the protein ubiquitination pathway was down-regulated by δ-tocotrienol treatment as described previously \[[@CR1]\].

The important signaling pathways modulated by tocotrienols are as follows: at the top of the list is "eukaryotic translation initiation factors" (EIF2) signaling pathway (Fig. [3](#Fig3){ref-type="fig"}). This is involved in protein synthesis, and requires a large number of polypeptides. EIF2 is a GTP-binding protein, which initiates specific forms of met-tRNA onto the ribosome. Its important function is to deliver charged initiator met-tRNA to the ribosome, it also identifies the translational starting site \[[@CR9]\]. This is followed by protein ubiquitination pathway, which plays a major role in the degradation of short-lived or regulatory proteins. It plays a role in a variety of cellular processes, such as cell cycle, cell proliferation, apoptosis, DNA repair, transcriptional regulation, cell surface receptors, ion channels regulation and antigen presentation, as outlined in Fig. [4](#Fig4){ref-type="fig"} \[[@CR10]\]. We have discussed the importance of ubiquitination in our several earlier publications \[[@CR11]--[@CR15]\].Fig. 3Effect on eukaryotic translation initiation factors (EIF2) signaling pathway in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. EIF2 was down-regulated by δ-tocotrienol treatment, which is involved in protein synthesis, requires a large number of polypeptides. EIF2 is a GTP-binding protein, which initiates specific form of met-tRNA onto the ribosomeFig. 4Effect on protein ubiquitination signaling pathway in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The protein ubiquitination pathway was down-regulated by δ-tocotrienol treatment. It plays a major role in the degradation of regulatory proteins, including a variety of cellular processes, such as cell cycle, cell proliferation, DNA repair, apoptosis, transcription regulation, cell surface receptors, ion channel regulation and antigen presentation

δ-Tocotrienol treatment of chronic hepatitis C patients also affects several other regulators in canonical pathways, we will limit our discussion to only important signaling and biomarkers associated with present investigation. The toll-like receptor signaling (TLRs) belongs to the family of pathogen-associated pattern recognition receptors, and bind to specific molecular patterns in bacteria and viruses. The pathogen-associated ligands include bacterial flagellin, viral DNA, lipopolysaccharide (LPS) and CpG DNA motifs. TLRs form a complex with different combinations of adopter molecules like MYD88, TRAF6 and TIRAP to initiate signal transduction upon ligand binding. This binding triggers a cascade of signaling events via the TLR-adapter complex, and downstream sigling molecules like p38MAPK. JNK. NF-κB activated and translocated into the nucleus, where they activate transcription regulators like c-Fos and c-Jun, leading to the induction of several pro-inflammatory cytokines, eventually leading to antibacterial and antiviral responses \[[@CR25], [@CR26]\]. Tocotrienol treatment causes a downregulation of the TLR pathways in hepatitis C patients. The toll-like receptor signaling pathways outlined in Fig. [5](#Fig5){ref-type="fig"}.Fig. 5Effect on toll-like receptor (TLRs) signaling pathways in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The TLRs were down-regulated by δ-tocotrienol treatment, these belong to the family of pathogen-associated receptors, and bind to a number of bacteria and viruses, such as viral DNA, lipopolysaccharide, and CpG DNA motifs. TLRs form a complex with different combinations of adapter molecules like MYD88, TRAF6 and TIRAP to initiate signal transduction upon ligand binding

The signal transducers and activators of transcription (STATs) are a family of cytoplasmic proteins with Src homology-2 (SH2) domains. STATs acts as a signal messenger and transcription factors. It participates in normal cellular responses to cytokines and growth factors. STATs pathways activated via tyrosine phosphorylation cascade after ligand binding by stimulation of the cytokine receptor-kinase complex and growth factor-receptor complex. The IL-6 cytokine activates STAT3 and STAT1. STAT3 encoded in human gene. The STAT3 signaling pathway (Fig. [6](#Fig6){ref-type="fig"}) plays an important role in normal development, particularly hematopoiesis, and regulates cancer metastasis by regulating the expression of genes that are critical to cell survival, cell proliferation, invasion, angiogenesis, and tumor immune evasion \[[@CR27]--[@CR29]\].Fig. 6Effect on signal transducer and activators of transcription (STATs) signaling pathways in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The STATs were down-regulated by δ-tocotrienol treatment, and belong to a family of cytoplasmic proteins with Src homology-2 (SH2) domains that acts as signal messenger and transcriptional factors and responses to cytokines and growth factors. The STAT pathways are activated via tyrosine phosphorylation cascade and play an important role in normal development of hematopoiesis, and regulates cancer metastasis by regulating the expression of genes that are critical to cell survival, cell proliferation, invasion, angiogenesis, and tumor immune evasion

The nuclear factor kappa B (NF-κB) transcription factors are key regulators of gene expression and acts in response to stress and the development of innate and acquired immunity \[[@CR30]\]. A multitude of extracellular stimuli (such as cytokines, infections, oxidative, DNA-damaging agents, UV light, osmotic shock) can lead to NF-κB activation. NF-κB activators mediate the site-specific phosphorylation of serine on IκB (inhibitor of NF-κB), resulting in IκB ubiquitination and subsequent proteasomal destruction \[[@CR31]\]. The pathway highlights the important components of the NF-κB signaling pathway outlined in (Fig. [7](#Fig7){ref-type="fig"}). Inhibiting this pathway by proteasome inhibitors would possibly expected to cause cell death of infected hepatic cells.Fig. 7Effect on nuclear factor kappaB (NF-κB) in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. δ-Tocotrienol modulates NF-κB transcription factors, which are key regulators of gene expression and act in response to stress and the development of innate and acquired immunity. A number of NF-κB activators mediate the site-specific phosphorylation of serine on IκB (inhibitor of NF-κB), there by marking IκB for ubiquitination and subsequent proteasomal destruction

The catalytic activity of iNOS is to kill or inhibit the growth of invading viruses and microorganisms. It produces nitric oxide from L-arginine \[[@CR32], [@CR33]\]. Nitric oxide is a free radical effector of the innate immune system that can directly inhibit pathogen replication. A variety of extracellular stimuli can activate signaling pathways that converge to initiate expression of iNOS. Moreover, components of cell wall of bacteria (lipopolysaccharide; LPS) or fungi trigger the innate immune signaling cascade leading to expression of iNOS \[[@CR34]--[@CR36]\]. This leads to activation of NF-κB and p38 MAPK signaling pathways \[[@CR37]\]. NF-κB in the nucleus binds to NF-κB elements in the iNOS 5′ flanking region, triggering iNOS transcription. Cytokines released from the infected host cell also activate nitric oxide production. IFNγ activates JAK family kinases to trigger JAK/STAT signaling, leading to synthesis of the transcription factor IRF1 and stimulation of a large number of iNOS mRNA transcription \[[@CR38]\]. The iNOS signaling pathways (Fig. [8](#Fig8){ref-type="fig"}) shows all possible regulators of production of nitric oxide, and highlights the important molecular events leads to production in macrophages. Collectively, IFN-γ induced by δ-tocotrienols would be expected to modulate the JAK/STAT pathway and NO production.Fig. 8Effect on nitric oxide synthase (iNOS) in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The iNOS was down-regulate by δ-tocotrienol treatment. It produces nitric oxide from L-arginine, a cytotoxic weapon generated by macrophages. The catalytic activity of iNOS is to kill or inhibit the growth of invading microorganisms. Nitric oxide is a free radical effector of the innate immune system that inhibits pathogen replication. A variety of extracellular stimuli (components of bacteria and fungi) can activate signaling pathways that help to initiate expression of iNOS

Interleukin-6 (IL-6) is a regulator of acute phase responses and a lymphocyte stimulatory factor. The central role of IL-6 is for the management of infectious and inflammatory diseases \[[@CR39]\]. IL-6 responses transmitted through glycoprotein 130 (GP130), which serves as the universal signal-transducing receptor subunit for all IL-6 related cytokines. Moreover, IL-6-type cytokines utilize tyrosine kinases of the Janus kinase (JAK) family and signal transducer/activators of STAT transcription family as major mediators of signal transduction \[[@CR40]\]. In addition to the JAK/STAT pathway of signal transduction, IL-6 also activates the extracellular signal-regulated kinases (ERK1/2) of the mitogen activated protein kinase (MAPK) pathway (Fig. [9](#Fig9){ref-type="fig"}). The upstream regulators of ERK1/2 include RAS and the src homology-2 containing proteins GRB2 and SHC. The SCH protein activate by JAK2 and thus serves as a link between the IL-6 activated JAK/STAT and RAS-MAPK pathways shown in IL-6 signaling pathway Fig. [9](#Fig9){ref-type="fig"} \[[@CR41]\]. Furthermore, phosphorylation of MAPKs in response to IL-6 activated RAS results in the activation of nuclear factor IL-6 (NF-IL-6), which in turn stimulates the transcription of the IL-6 gene. IL-6 gene transcription is also stimulated by TNF-α and IL-1 via activation of NF-κB \[[@CR41]--[@CR43]\]. The tumor necrosis factor receptor (TNFR1) belongs to a family of 20 in mammalian cells.Fig. 9Effect on interleukin-6 (IL-6) regulator of gene expression in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The IL-6 was down-regulated by δ-tocotrienol treatment, and is considered a regulator of acute phase responses and a lymphocyte stimulatory factor. The most important role of IL-6 is for the management of infection and inflammatory diseases. The transcription of IL-6 gene is stimulated by TNF-α and IL-1 via activation of NF-κB

TNF-α, an important cytokine involves in cell proliferation, differentiation, and apoptosis modulate immune responses and induction of inflammation \[[@CR44]\]. TNF-α functions through two receptors, TNFR1 TNFR2. TNFR1 is expressed in human tissue and TNFR2 expressed in immune cells (Fig. [10](#Fig10){ref-type="fig"}) \[[@CR44], [@CR45]\]. δ-Tocotrienol also inhibits expression of IL-6 and TNFR induction in chronic hepatitis C patients.Fig. 10Effect on tumor necrosis factor receptor1 (TNFR1) regulator of gene expression in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The TNFR1 was down-regulated by δ-tocotrienol treatment, and belongs to a family of 20 in mammalian cells. TNF-α is an important cytokine involved in cell proliferation, differentiation, apoptosis, modulates immune responses and induction of inflammation. TNF-α functions through two receptors, TNFR1 and TNFR2. TNFR1 is expressed in human tissue, and TNFR2 is expressed in immune cells

Autophagy is a basic catabolic mechanism that involves cellular degradation of unnecessary or dysfunctional cellular components through the actions of liposome \[[@CR46], [@CR47]\]. Autophagy is generally activate by condition of nutrient deprivation but has also been associated with physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer \[[@CR47]--[@CR49]\]. The mammalian target of rapamycin (mTOR) kinase is a critical regulator of autophagy induction, with activated mTOR (AKT and MAPK signaling) suppressing autophagy, and negative regulation of mTOR (AMPK and p53 signaling) promoting it \[[@CR48]\]. The autophagy pathway (Fig. [11](#Fig11){ref-type="fig"}) highlights the key molecular events involved in triggering autophagy. Inhibiting the proteasome activity also causes the onset of autophagy, as observed with δ-tocotrienol treatment.Fig. 11Effect on autophagy in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. The autophagy modulated by δ-tocotrienol treatment of hepatitis C patients:. Autophagy is a general term for the basic catabolic mechanism that involves cellular degradation of unnecessary or dysfunctional cellular components through the actions of lysosome. Autophagy is generally activated by conditions of nutrient deprivation but it has also been associated with physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer. The mammalian target of rapamycin (mTOR) kinase is a critical regulator of autophagy induction

Whereas, apoptosis is a coordinated energy-dependent process that involves the activation of a group of cysteine proteases called caspases and a cascade of events that link the initiating stimuli to programmed cell death \[[@CR50]\]. The two main pathways of apoptosis are the intrinsic and extrinsic pathways. Each pathway requires specific triggers to initiate a cascade of molecular events that converge at the stage of caspase-3 activation \[[@CR50]\]. The activation of caspase-3 in turn triggers an execution pathway resulting in characteristic cytomorphological features including cell shrinkage, membrane blabbing, chromatin condensation and DNA fragmentation \[[@CR51]\]. Further details of intrinsic and extrinsic pathways were found in the attached Ingenuity Apoptosis Signaling Pathway (Fig. [12](#Fig12){ref-type="fig"}), which highlights the key molecular events involved in trigging apoptosis.Fig. 12Effect on apoptosis in plasma of total mRNAs obtained from δ-tocotrienol treatment of hepatitis C patients. Apoptosis modulated by δ-tocotrienol treatment of hepatitis C patients. Apoptosis is a coordinated energy-dependent process that involves the activation of a group of cysteine proteases called caspases and a cascade of events that link the initiating stimuli to programmed cell death. There are two main pathways of apoptosis, the intrinsic and extrinsic as shown here

Beside these, other regulators were also affected by δ-tocotrienol treatment of hepatitis C patients, and they are interferon signaling, IL-2 signaling, and HMGB1 signaling, Cardiac hypertrophy signaling, Th1 and Th2 activation pathway, production of nitric oxide and reactive oxygen species in macrophages, Osteoarthritis pathway, PPAR signaling, type,I diabetes mellitus signaling, Type II diabetes mellitus, and insulin receptor signaling. In summary, EIF2 signaling regulator is at the top of the canonical pathway list but its fold change expression value is 221 as compared to protein ubiquitination pathway is 265 fold. On the other hand, osteoarthritis (210 fold), mammalian target of rapamycin (mTOR-201 fold), IL-8 (197 fold), Th1-Th2 (185 fold), PPARα/RXRα activation (180 fold), NF-κB (181 fold), IL-6 (128 fold), Type II diabetes mellitus signaling (128 fold), and nitric oxide signaling in cardiovascular system (113 fold), all have lower fold change expression compared to EIF2. This indicates the importance of δ-tocotrienol on so many biological activities and signaling pathways (Table [11](#Tab11){ref-type="table"}). The importance of most of these regulators was discussed in our several publications during course of the last decade \[[@CR1], [@CR11]--[@CR15]\].

Conclusions {#Sec15}
===========

Present results of fold-change expression data analyzed by "Ingenuity Pathway Analysis" describe the effect of δ-tocotrienol in chronic hepatitis C patients on biological mechanisms at molecular level. It also revealed an insight of correlation of signaling pathways and transcriptional factors. Recently, two comprehensive reviews on the several biological activities of tocotrienols as hypocholesterolemic, anti-inflammatory, anticancer, antioxidant, neuroprotective, skin protection benefits, bone health and longevity have been published \[[@CR52], [@CR53]\]. These articles also cover the beneficial properties of different isomers of tocotrienols treatment along with possible mechanisms, signaling pathways in breast, prostate, pancreas, rectal cancers in cell lines and humans \[[@CR52], [@CR53]\]. Major signaling pathways that were affected by δ-tocotrienol treatment in chronic hepatitis C subjects are summarized in the Table [12](#Tab12){ref-type="table"}. The collective results indicate that tocotrienols inhibit cancer cell proliferation, promotes cell cycle arrest, decreases angiogenesis and acts via multiple signaling pathways \[[@CR1]\]. Our present results are consistent with these conclusions and δ-tocotrienol treatment of hepatitis C patients, acts by increasing cell death, and necrosis of malignant tumors, and by decreasing viral infection, cellular growth and proliferation, decreasing endocrine system disorders such as diabetes mellitus, and mobilization of calcium. Therefore, tocotrienols can safely be used for hepatitis C patients, without any side effects.Table 12Major signaling pathways affected by δ-tocotrienol treatment in chronic hepatitis C subjectsDown-regulated by δ -tocotrienol treatmentUp-regulated by δ-tocotrienol treatmentProliferation of immune cellsCell death and survivalProliferation of mononuclear leukocytesNecrosis of malignant tumorViral infectionGene expressionFree radical scavengingOrganismal DeathEndocrine system disorder, Diabetes mellitusCell death of cancer cellsMobilization of Ca2+Cell death of tumorsReplication of virusHIV infection, replication of Influenza virus
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Additional file 1:**Table S1.** Effect of d-tocotrienol on down-regulation of gene expression of \"Molecules\" (1-75) of IPA analyses in hepatitis C patients. (XLS 68 kb) Additional file 2:**Table S2.** Effect of d-tocotrienol on down-regulation of gene expression of \"Molecules\" (76-150) of IPA analyses in hepatitis C patients. (XLS 68 kb) Additional file 3:**Table S3.** Effect of d-tocotrienol on down-regulation of gene expression of \"Molecules\" (151-220) of IPA analyses in hepatitis C patients. (XLS 67 kb)

EIF2

:   Eukaryotic translation initiation factors

ICAM1

:   Intercellular adhesion molecule1

IL-6

:   Interleukin-6

IPA

:   Ingenuity Pathway Analysis

mTOR

:   Mammalian target of rapamycin

NF-κB

:   Nuclear factor kappaB

TNF-α

:   Τumor necrosis factor-α

VCAM1

:   Vascular cell adhesion molecule1
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